Vadim Tsyvunin

Vadim Tsyvunin

Auto-generated profile, based on publicly available information

Vadim Tsyvunin

National University of Pharmacy, Hryhoriia Skovorody str., 53, Kharkiv, 61002; LLC "ORGANOSYN LTD", Akademika Knyshova str., 6-L, Kyiv, 03022

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Epilepsy Research
Verified
Journal Article
Closed access
VTVadim Tsyvunin
Vadim Tsyvunin
SSSergiy Shtrygol'
Sergiy Shtrygol'
DSDiana Shtrygol'
Diana Shtrygol'

6 December 2015 in Scientia Pharmaceutica
Verified
Journal Article
Open access
PDF file
YPYuliya Prokopenko
Yuliya Prokopenko
VTVadim Tsyvunin
Vadim Tsyvunin
SSSergey Shtrygol’
Sergey Shtrygol’
VGVictoriya A. Georgiyants
Victoriya A. Georgiyants
The present study aimed to investigate the role of several biologically active compounds from Fumaria schleicheri Soy.-Will. in anticonvulsant models. The flavonoid fraction, alkaloid fraction, individual alkaloid protopine, and polysaccharide-protein complex were isolated from the Fumaria schleicheri herb and studied along with Fumaria schleicheri dry extract in mice with pentylenetetrazole-induced seizures. According to empirical results, the expressed anticonvulsant effect of Fumaria schleicheri dry extract depends on the synergism of biologically active compounds in herbal medicine, although some individual substances (mostly protopine and the protein-polysaccharide fraction) have shown moderate anti-seizure activity.

1 October 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
WKWassim Mokhamad El Kayal
Wassim Mokhamad El Kayal
SSSergiy Yu Shtrygol
Sergiy Yu Shtrygol
SZSergiy V. Zalevskyi
Sergiy V. Zalevskyi
ASAmjad abu Shark
Amjad abu Shark
VTVadim V. Tsyvunin
Vadim V. Tsyvunin
VGVictoriya A. Georgiyants
Victoriya A. Georgiyants

13 December 2021 in ScienceRise: Pharmaceutical Science
Verified
Journal Article
Open access
PDF file
VTVadim Tsyvunin
Vadim Tsyvunin
ДШДіана Штриголь
Діана Штриголь
IHIhnat Havrylov
Ihnat Havrylov
DSDiana Shtrygol’
Diana Shtrygol’
"Non-antiepileptic" drugs have a strong potential as adjuvants in multidrug-resistant epilepsy treatment. In previous study the influence of low doses of digoxin, which do not affect the myocardium, on the anticonvulsant potential of classical commonly used anti-epileptic drugs under conditions of seizures, induced by pentylenetetrazole and maximal electroshock, has been investigated. The aim of the study was to investigate the influence of digoxin at a sub-cardiotonic dose on the anticonvulsant potential of carbamazepine and lamotrigine in experimental seizures with different neurochemical mechanisms. Material and methods: A total of 192 random-bred male albino mice weighting 22–25 g were used. Carbamazepine and lamotrigine were administered intragastrically in conditionally effective (ED50) and sub-effective (½ ED50) doses: carbamazepine at doses of 100 and 50 mg/kg; lamotrigine at doses of 25 and 12.5 mg/kg. Digoxin was administered subcutaneously at a sub-cardiotonic dose of 0.8 mg/kg as an adjuvant to carbamazepine and lamotrigine in ½ ED50. Picrotoxin (2.5 mg/kg subcutaneously); thiosemicarbazide (25 mg/kg intraperitoneally); strychnine (1.2 mg/kg subcutaneously); camphor (1000 mg/kg intraperitoneally) were used as convulsant agents. Results: It was found that digoxin not only has its own permanent anticonvulsant effect on different models of paroxysms with different neurochemical mechanisms of development, but also significantly enhances the anticonvulsant potential of carbamazepine (to a lesser extent – lamotrigine) regardless of the pathogenesis of experimental paroxysms. Conclusion: Based on the results, it can be concluded that digoxin has a high potential as an adjuvant medicine in complex epilepsy treatment because it enhances the efficiency of low-dose traditional anticonvulsants carbamazepine and lamotrigine

1 January 2021 in The Thai Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
VTVadim Tsyvunin
Vadim Tsyvunin
SSSergiy Shtrygol
Sergiy Shtrygol
DSDiana Shtrygol
Diana Shtrygol
MMMariia Mishchenko
Mariia Mishchenko
IKIhor Kapelka
Ihor Kapelka
ATAndriy Tara
Andriy Tara
Introduction: The worldwide high amount of multidrug-resistant epilepsy patients makes it urgent to find new approaches to treating, including the use of combinations of classic anticonvulsants with drugs that have an exclusively original mechanism of action, in particular digoxin. Objective: The aim of this work was to investigate the influence of low-dose cardiac glycoside digoxin on the anticonvulsant effect of carbamazepine and lamotrigine. Methods: Basic models of pentylenetetrazole- induced seizures and electroinduced paroxysms (maximal electroshock) in mice were used. Classic anticonvulsants were administered intragastrically in conditionally effective and sub-effective doses at 30 min, digoxin – subcutaneously at a dose of 0.8 mg/kg (1/10 LD50) at 15 min before seizures induction. Pentylenetetrazole at a dose of 80 mg/kg was administered subcutaneously. The maximal electroshock was reproduced by transmitting an electric current (strength – 50 mA, frequency – 50 Hz) through the corneal electrodes for 0.2 sec. Results: It was established that the co-administration of digoxin with carbamazepine and lamotrigine in sub-effective doses render a marked anticonvulsant action on the model of pentylenetetrazole-induced seizures as well as on seizures induced by maximal electroshock. Digoxin can reduce the doses of carbamazepine and lamotrigine with a corresponding reduction in the risk of side effects without compromising treatment efficacy. Conclusion: Digoxin can be a valuable component of complex therapy of epilepsy

1 July 2016 in ScienceRise: Pharmaceutical Science
Verified
Journal Article
Open access
PDF file
VTVadim Tsyvunin
Vadim Tsyvunin
SSSergey Shtrygol’
Sergey Shtrygol’
YPYuliya Prokopenko
Yuliya Prokopenko
VGVictoriya A. Georgiyants
Victoriya A. Georgiyants
NBNataliya Blyznyuk
Nataliya Blyznyuk
Мета. Провести фармакологічний скринінг 48 сухих екстрактів, отриманих із 18 видів рослин 8 родин, протисудомні властивості яких раніше не вивчались, здійснити аналіз хімічного складу екстрактів із виразними анти- та проконвульсивними властивостями, а також оцінити взаємозв’язок між фармакологічним ефектом рослинних препаратів та їх фітохімічним складом. Методи. На моделі пентилентетразолових судом у мишей було встановлено ефект 48 сухих рослинних екстрактів із різним хімічним складом. Екстракти стандартизували за вмістом алкалоїдів, флавоноїдів та поліфенольних сполук відповідно до вимог Європейської Фармакопеї (ВЕТШХ, ВЕРХ, УЕРХ, ГХ з мас-детектором). Результати. За інтегральним показником ефективності – зниженню летальності – встановлено, що 11 рослинних екстрактів мають виразні протисудомні властивості, 10 фітопрепаратів діють як проконвульсанти, а інші 27 екстрактів практично не вливають на експериментальні судоми. Визначений зв’язок між фармакологічним ефектом та фітохімічним складом рослин, з яких одержували екстракти, а також видовою приналежністю рослини-хазяїна (для паратизуючого виду – омели білої) та ступенем полярності екстрагенту. Для екстрактів із вираженими анти- та проконвульсивними властивостями визначено їх хімічний склад. Висновки. Детальний аналіз взаємозв’язку між фітохімічним складом та впливом екстрактів на перебіг судом показав, що протисудомна дія екстрактів найвірогідніше обумовлена високим вмістом рутину, проте для рослин із виразними проконвульсивними властивостями роль окремих груп біологічно активних сполук залишається не визначеною